<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="other" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47360/1995-4484-2024-365-368</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-3601</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АКТУАЛЬНОЕ ИНТЕРВЬЮ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>TOPICAL INTERVIEW</subject></subj-group></article-categories><title-group><article-title>Перикардит как междисциплинарная проблема. В преддверии обновления рекомендаций Европейского общества кардиологов</article-title><trans-title-group xml:lang="en"><trans-title>Pericarditis as an interdisciplinary problem. In anticipation of the update of the European Society of Cardiology guidelines</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Имазио</surname><given-names>М.</given-names></name><name name-style="western" xml:lang="en"><surname>Imazio</surname><given-names>Massimo</given-names></name></name-alternatives><bio xml:lang="ru"><p>33100, Udine, via Palladio, 8 </p><p>33100, Udine, Piazzale Santa Maria della Misericordia, 15 </p></bio><bio xml:lang="en"><p>33100, Udine, via Palladio, 8 </p><p>33100, Udine, Piazzale Santa Maria della Misericordia, 15 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сукмарова</surname><given-names>З. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Sukmarova</surname><given-names>Zulfiya N.</given-names></name></name-alternatives><bio xml:lang="en"><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Насонов</surname><given-names>Е. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Nasonov</surname><given-names>Evgeny L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Евгений Львович Насонов</p><p>115522, Москва, Каширское шоссе, 34а</p><p>119991, Москва, ул. Трубецкая, 8, стр. 2</p></bio><bio xml:lang="en"><p>115522, Moscow, Kashirskoye Highway, 34A</p><p>119991, Moscow, Trubetskaya str., 8, building 2</p></bio><email xlink:type="simple">nasonov@irramn.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Department  of Medicine (DMED), University of Udine; Cardiothoracic Department, University Hospital Santa Maria della Misericordia</institution><country>Италия</country></aff><aff xml:lang="en"><institution>Department  of Medicine (DMED), University of Udine; Cardiothoracic Department, University Hospital Santa Maria della Misericordia</institution><country>Italy</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>02</day><month>09</month><year>2024</year></pub-date><volume>62</volume><issue>4</issue><elocation-id>365–368</elocation-id><permissions><copyright-statement>Copyright &amp;#x00A9; Имазио М., Сукмарова З.Н., Насонов Е.Л., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Имазио М., Сукмарова З.Н., Насонов Е.Л.</copyright-holder><copyright-holder xml:lang="en">Imazio M., Sukmarova Z.N., Nasonov E.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/3601">https://rsp.mediar-press.net/rsp/article/view/3601</self-uri><abstract><p>Доктор Массимо Имазио (Massimo Imazio) получил степень по медицине и хирургии в Туринском университете (Италия) в 1994 г. (с отличием), национальную квалификацию врача в 1995 г., степень по специальности «кардиология» в Туринском университете в 1998 г. (с отличием). Доктор Имазио – доцент и профессор кардиологии Национального квалификационного центра и профессор кардиологии и анатомии, преподаватель в специализированных школах кардиологии и внутренней медицины Туринского университета.</p><p>Он является одним самых цитируемых ученых в области воспалительных заболеваний перикарда. Перикардит относится к числу наиболее распространенных форм воспалительных заболеваний сердечнососудистой системы, проблемы которого находятся на стыке кардиологии, иммунологии и ревматологии. Противовоспалительная терапия является основным направлением лечения перикардита. Европейским рекомендациям по диагностике и терапии перикардита около 10 лет, и в 2025 г. ожидается их очередное обновление. Профессор Массимо Имазио, который является членом Рабочей группы по диагностике и лечению заболеваний перикарда Европейского общества кардиологов (ESC, European Society of Cardiology) и Европейской ассоциации кардиоторакальной хирургии (EACTS, European Association for Cardio-Thoracic Surgery) 2015 г. и председателем рабочей рекомендаций ESC 2025 г. по миокардиту и перикардиту, дал интервью, касающееся наиболее актуальных проблем диагностики и лечения перикардита.</p></abstract><trans-abstract xml:lang="en"><p>Pericarditis is one of the most common forms of inflammatory diseases of the cardiovascular system, diseases that are observed in cardiology, immunology and rheumatology. Anti-inflammatory therapy is the mainstay of treatment for pericarditis. Low recommendations for the diagnosis and treatment of pericarditis for about 10 years, and in 2025, guide their next update. Professor Massimo Imasio, who is a member of the Working Group on Diagnosis and Various Diseases of the Pericardium of the European Society of Cardiology (ESC, European Society of Cardiology) and the Association of Cardiothoracic Surgery (EACTS, European Association of Cardiothoracic Surgery) 2015 and Chairman of the 2025 ESC Working Guidelines on Myocarditis and Pericarditis, gave an interview regarding the most pressing issues in the diagnosis and treatment of pericarditis.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>перикардит</kwd><kwd>идиопатический рецидивирующий перикардит</kwd><kwd>иммуновоспалительные ревматические заболевания</kwd><kwd>колхицин</kwd><kwd>интерлейкин 1</kwd><kwd>анакинра</kwd></kwd-group><kwd-group xml:lang="en"><kwd>pericarditis</kwd><kwd>idiopathic recurrent pericarditis</kwd><kwd>immunoinflammatory rheumatic diseases</kwd><kwd>colchicine</kwd><kwd>interleukin 1</kwd><kwd>anakinra</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al.; ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921-2964. doi: 10.1093/eurheartj/ehv318</mixed-citation><mixed-citation xml:lang="en">Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al.; ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36(42):2921-2964. doi: 10.1093/eurheartj/ehv318</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Mann DL. The emerging field of cardioimmunology: Past, present and foreseeable future. Circ Res. 2024;134(12):1663-1680. doi: 10.1161/CIRCRESAHA.123.323656</mixed-citation><mixed-citation xml:lang="en">Mann DL. The emerging field of cardioimmunology: Past, present and foreseeable future. Circ Res. 2024;134(12):1663-1680. doi: 10.1161/CIRCRESAHA.123.323656</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Abbate A, Weber B, Garschick M, Adamo L, Beavers C. Inflammation and heart diseases: Immunology, cardiology, and rheumatology. J Cardiovasc Pharmacol. 2024;83(5):361-363. doi: 10.1097/FJC.0000000000001531</mixed-citation><mixed-citation xml:lang="en">Abbate A, Weber B, Garschick M, Adamo L, Beavers C. Inflammation and heart diseases: Immunology, cardiology, and rheumatology. J Cardiovasc Pharmacol. 2024;83(5):361-363. doi: 10.1097/FJC.0000000000001531</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Imazio M. Medical therapy of pericarditis: tips and tricks for clinical practice. J Cardiovasc Med (Hagerstown). 2024;25(6):420-425. doi: 10.2459/JCM.0000000000001618</mixed-citation><mixed-citation xml:lang="en">Imazio M. Medical therapy of pericarditis: tips and tricks for clinical practice. J Cardiovasc Med (Hagerstown). 2024;25(6):420-425. doi: 10.2459/JCM.0000000000001618</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Furqan MM, Verma BR, Cremer PC, Imazio M, Klein AL. Pericardial diseases in COVID19: A contemporary review. Curr Cardiol Rep. 2021;23(7):90. doi: 10.1007/s11886-021-01519-x</mixed-citation><mixed-citation xml:lang="en">Furqan MM, Verma BR, Cremer PC, Imazio M, Klein AL. Pericardial diseases in COVID19: A contemporary review. Curr Cardiol Rep. 2021;23(7):90. doi: 10.1007/s11886-021-01519-x</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ghantous E, Szekely Y, Lichter Y, Levi E, Taieb P, Banai A, et al. Pericardial involvement in patients hospitalized with COVID-19: Prevalence, associates, and clinical implications. J Am Heart Assoc. 2022;11(7):e024363. doi: 10.1161/JAHA.121.024363</mixed-citation><mixed-citation xml:lang="en">Ghantous E, Szekely Y, Lichter Y, Levi E, Taieb P, Banai A, et al. Pericardial involvement in patients hospitalized with COVID-19: Prevalence, associates, and clinical implications. J Am Heart Assoc. 2022;11(7):e024363. doi: 10.1161/JAHA.121.024363</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Corrao G, Franchi M, Cereda D, Bortolan F, Leoni O, Vignati E, et al. Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID19 vaccination: A cohort study in Lombardy, Italy. BMC Infect Dis. 2022;22(1):844. doi: 10.1186/s12879-022-07823-3</mixed-citation><mixed-citation xml:lang="en">Corrao G, Franchi M, Cereda D, Bortolan F, Leoni O, Vignati E, et al. Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID19 vaccination: A cohort study in Lombardy, Italy. BMC Infect Dis. 2022;22(1):844. doi: 10.1186/s12879-022-07823-3</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-590. doi: 10.1038/s41591-022-01689-3</mixed-citation><mixed-citation xml:lang="en">Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-590. doi: 10.1038/s41591-022-01689-3</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Сукмарова ЗН, Овчинников ЮВ, Гудима ГО, Ибрагимова ФМ, Афонина ОВ, Мачкалян КЭ. Усиление эхо-сигнала от перикарда у реципиентов вакцин против SARS-CoV-2. Инфекционные болезни. 2021;19(4):43-50. doi: 10.20953/1729-9225-2021-4-43-50</mixed-citation><mixed-citation xml:lang="en">Sukmarova ZN, Ovchinnikov YuV, Gudima GO, Ibragimova FM, Afonina OV, Machkalyan KE. Hyperechogenic signal from the pericardium after vaccination against SARS-CoV-2. Infectious Diseases. 2021; 19(4):43-50. (In Russ.)]. doi: 10.20953/1729-9225-2021-4-43-50</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Сукмарова ЗН, Попкова ТВ, Белов БС. Проблемы иммунопатологии и перспективы фармакотерапии идиопатического рецидивирующего перикардита: применение ингибитора интерлейкина 1 (Анакинра). Научно-практическая ревматология. 2023;61(1):47-61. doi: 10.47360/1995-4484-2023-47-61</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Sukmarova ZN, Popkova TV, Belov BS. Problems of immunopathology and prospects for pharmacotherapy of idiopathic recurrent pericarditis: Using an interleukin 1 inhibitor (Anakinra). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(1):47-61 (In Russ.)]. doi: 10.47360/1995-4484-2023-47-61</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Imazio M, Brucato A, Maestroni S, Cumetti D, Dominelli A, Natale G, et al. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: Implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation. 2011;123(10): 1092-1097. doi: 10.1161/CIRCULATIONAHA.110.986372</mixed-citation><mixed-citation xml:lang="en">Imazio M, Brucato A, Maestroni S, Cumetti D, Dominelli A, Natale G, et al. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: Implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation. 2011;123(10): 1092-1097. doi: 10.1161/CIRCULATIONAHA.110.986372</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Imazio M. Pericardial involvement in systemic inflammatory diseases. Heart. 2011;97(22):1882-1892. doi: 10.1136/heartjnl-2011-300054</mixed-citation><mixed-citation xml:lang="en">Imazio M. Pericardial involvement in systemic inflammatory diseases. Heart. 2011;97(22):1882-1892. doi: 10.1136/heartjnl-2011-300054</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Imazio M, Demichelis B, Parrini I, Giuggia M, Cecchi E, Gaschino G, et al. Day-hospital treatment of acute pericarditis: A management program for outpatient therapy. J Am Coll Cardiol. 2004;43(6):1042-1046. doi: 10.1016/j.jacc.2003.09.055</mixed-citation><mixed-citation xml:lang="en">Imazio M, Demichelis B, Parrini I, Giuggia M, Cecchi E, Gaschino G, et al. Day-hospital treatment of acute pericarditis: A management program for outpatient therapy. J Am Coll Cardiol. 2004;43(6):1042-1046. doi: 10.1016/j.jacc.2003.09.055</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Lowdose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404-410. doi: 10.1016/j.jacc.2012.10.027</mixed-citation><mixed-citation xml:lang="en">Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Lowdose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404-410. doi: 10.1016/j.jacc.2012.10.027</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497-2505. doi: 10.1056/NEJMoa1912388</mixed-citation><mixed-citation xml:lang="en">Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497-2505. doi: 10.1056/NEJMoa1912388</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Samuel M, Tardif JC, Khairy P, Roubille F, Waters DD, Grégoire JC, et al. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J Qual Care Clin Outcomes. 2021;7(5):486-495. doi: 10.1093/ehjqcco/qcaa045</mixed-citation><mixed-citation xml:lang="en">Samuel M, Tardif JC, Khairy P, Roubille F, Waters DD, Grégoire JC, et al. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J Qual Care Clin Outcomes. 2021;7(5):486-495. doi: 10.1093/ehjqcco/qcaa045</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
